PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-32.96%
Cash & equivalents declining -32.96% while AVXL's grows 10.35%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-32.96%
Below half of AVXL's 10.35%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.20%
Below half of AVXL's 10.47%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.82%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
305.95%
Higher Total Non-Current Assets Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-28.88%
Below half of AVXL's 10.45%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-28.35%
Above 1.5x AVXL's -5.88%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.97%
Less than half of AVXL's 173.83%. David Dodd sees fewer expansions in other current obligations.
-23.54%
Above 1.5x AVXL's -3.42%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.54%
Above 1.5x AVXL's -3.42%. Michael Burry sees a potential leverage warning sign.
2.39%
1.25-1.5x AVXL's 1.74%. Martin Whitman sees potential dilution risk vs. competitor approach.
-4.88%
≥ 1.5x AVXL's -1.91%. David Dodd sees higher yoy retained profits than competitor.
-7.49%
Higher AOCI Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-31.10%
Below half AVXL's 12.03%. Michael Burry sees potential underperformance in building shareholder capital.
-28.88%
Below half AVXL's 10.45%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.96%
Less than half of AVXL's -10.35%. David Dodd sees better deleveraging or stronger cash buildup than competitor.